TY - JOUR
T1 - Is There a Third-Line Therapy for Metastatic Colorectal Cancer?
AU - Grothey, Axel
PY - 2006/12
Y1 - 2006/12
N2 - Selection of third-line treatment in metastatic colorectal cancer depends on the agents that have been used in prior therapy. A principle in treatment is to use all five of the active drugs in this setting (5-fluorouracil [5-FU], oxaliplatin, irinotecan, cetuximab, and bevacizumab) during the patient's overall treatment course for metastatic disease because cumulative use of available active drugs appears to increase overall survival. Currently, 5-FU/leucovorin (5-FU/LV)/oxaliplatin (FOLFOX) or 5-FU/LV plus irinotecan (FOLFIRI) can be considered standard therapy in first-line treatment, with cross-over irinotecan or oxaliplatin-containing regimens as a component of several possible second-line regimens. On this scenario, third-line treatment can include the combination of irinotecan with cetuximab or bevacizumab or both or the use of cetuximab and bevacizumab in combination. Data from randomized trials on third-line treatment are needed.
AB - Selection of third-line treatment in metastatic colorectal cancer depends on the agents that have been used in prior therapy. A principle in treatment is to use all five of the active drugs in this setting (5-fluorouracil [5-FU], oxaliplatin, irinotecan, cetuximab, and bevacizumab) during the patient's overall treatment course for metastatic disease because cumulative use of available active drugs appears to increase overall survival. Currently, 5-FU/leucovorin (5-FU/LV)/oxaliplatin (FOLFOX) or 5-FU/LV plus irinotecan (FOLFIRI) can be considered standard therapy in first-line treatment, with cross-over irinotecan or oxaliplatin-containing regimens as a component of several possible second-line regimens. On this scenario, third-line treatment can include the combination of irinotecan with cetuximab or bevacizumab or both or the use of cetuximab and bevacizumab in combination. Data from randomized trials on third-line treatment are needed.
UR - http://www.scopus.com/inward/record.url?scp=33845415637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845415637&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2006.10.007
DO - 10.1053/j.seminoncol.2006.10.007
M3 - Article
C2 - 17178284
AN - SCOPUS:33845415637
SN - 0093-7754
VL - 33
SP - 36
EP - 38
JO - Seminars in oncology
JF - Seminars in oncology
IS - SUPPL. 11
ER -